Literature DB >> 30621965

Blood Disorders in Patients Undergoing Transcatheter Aortic Valve Replacement: A Review.

Hugo De Larochellière1, Rishi Puri2, John W Eikelboom3, Josep Rodés-Cabau4.   

Abstract

Transcatheter aortic valve replacement (TAVR) is well established for treating patients with severe aortic stenosis considered at intermediate to high surgical risk. Blood disorders such as anemia, thrombocytopenia, and acquired type 2A von Willebrand disease are relatively frequent in TAVR candidates, and multiple studies to date have highlighted their potential clinical association with mortality and/or bleeding complications post-TAVR. The present review provides an overview of various blood disorders observed pre- and post-TAVR, with special focus on their incidence, etiology, clinical association, and management.
Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  anemia; aortic stenosis; hemostasis; thrombocytopenia

Year:  2019        PMID: 30621965     DOI: 10.1016/j.jcin.2018.09.041

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  9 in total

1.  Prolonged Clotting Time Among Patients Undergoing Transcatheter Aortic Valve Replacement.

Authors:  Harold L Dauerman; Christine M DeStephan; Heidi Taatjes Sommer; Kathryn C Kurchena; Michael DeSarno; Erika G Mendoza; Amy Henderson; David J Schneider
Journal:  J Am Coll Cardiol       Date:  2019-08-13       Impact factor: 24.094

2.  Anemia and risk of periprocedural cerebral injury detected by diffusion-weighted magnetic resonance imaging in patients undergoing transcatheter aortic valve replacement.

Authors:  Stella Ng; Qi-Feng Zhu; Ju-Bo Jiang; Chun-Hui Liu; Jia-Qi Fan; Ye-Ming Xu; Xian-Bao Liu; Jian-An Wang
Journal:  World J Emerg Med       Date:  2022

3.  Academic Research Consortium High Bleeding Risk Criteria associated with 2-year bleeding events and mortality after transcatheter aortic valve replacement discharge: a Japanese Multicentre Prospective OCEAN-TAVI Registry Study.

Authors:  Kazuki Mizutani; Gaku Nakazawa; Tomohiro Yamaguchi; Mana Ogawa; Tsukasa Okai; Fumiaki Yashima; Toru Naganuma; Futoshi Yamanaka; Norio Tada; Kensuke Takagi; Masahiro Yamawaki; Hiroshi Ueno; Minoru Tabata; Shinichi Shirai; Yusuke Watanabe; Masanori Yamamoto; Kentaro Hayashida
Journal:  Eur Heart J Open       Date:  2021-11-15

4.  Systemic bevacizumab for refractory bleeding and transfusion-dependent anemia in Heyde syndrome.

Authors:  Andrew B Song; Rahul Sakhuja; Nancy M Gracin; Ronald Weinger; Raj S Kasthuri; Hanny Al-Samkari
Journal:  Blood Adv       Date:  2021-10-12

Review 5.  Anticoagulation after Transcatheter Aortic Valve Implantation: Current Status.

Authors:  Antonio Greco; Davide Capodanno
Journal:  Interv Cardiol       Date:  2020-04-23

6.  Potential Role and Prognostic Value of Erythropoietin Levels in Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement.

Authors:  Silvia Mas-Peiro; Philipp C Seppelt; Roberta De Rosa; Marie-Isabel Murray; Jörg Yogarajah; Alexander Berkowitsch; Stephan Fichtlscherer; Andreas M Zeiher; Mariuca Vasa-Nicotera
Journal:  Front Cardiovasc Med       Date:  2020-11-30

Review 7.  Serotonin-A Driver of Progressive Heart Valve Disease.

Authors:  Helge Waldum; Alexander Wahba
Journal:  Front Cardiovasc Med       Date:  2022-01-28

Review 8.  Multimodal Treatment and Diagnostic Modalities in the Setting of Heyde's Syndrome: A Systematic Review.

Authors:  Dawood Jamil; Hadrian Hoang-Vu Tran; Mafaz Mansoor; Samia Rauf Bbutt; Travis Satnarine; Pranuthi Ratna; Aditi Sarker; Adarsh Srinivas Ramesh; Carlos Munoz Tello; Lubna Mohammed
Journal:  Cureus       Date:  2022-08-16

9.  Intravenous iron supplement for iron deficiency in patients with severe aortic stenosis scheduled for transcatheter aortic valve implantation: results of the IIISAS randomised trial.

Authors:  Anette B Kvaslerud; Sara Bardan; Kristoffer Andresen; Sophie F Kløve; Morten W Fagerland; Thor Edvardsen; Lars Gullestad; Kaspar Broch
Journal:  Eur J Heart Fail       Date:  2022-06-03       Impact factor: 17.349

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.